Javascript must be enabled to continue!
The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection
View through CrossRef
Abstract
Cirrhosis is a leading cause of death among patients infected with human immunodeficiency virus (HIV). We sought to determine risk factors for and time trends in the prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma (HCC) among patients diagnosed with HIV who received care in the Veterans Affairs (VA) health care system nationally between 1996 and 2009 (n = 24,040 in 2009). Among patients coinfected with HIV and hepatitis C virus (HCV), there was a dramatic increase in the prevalence of cirrhosis (3.5%-13.2%), decompensated cirrhosis (1.9%-5.8%), and HCC (0.07%-1.6%). Little increase was observed among patients without HCV coinfection in the prevalence of cirrhosis (1.7%-2.2%), decompensated cirrhosis (1.1%-1.2%), and HCC (0.03%-0.13%). In 2009, HCV infection was present in the majority of patients with HIV who had cirrhosis (66%), decompensated cirrhosis (62%), and HCC (80%). Independent risk factors for cirrhosis included HCV infection (adjusted odds ratio [AOR], 5.82; 95% confidence interval [CI], 5.0-6.7), hepatitis B virus (HBV) infection (AOR, 2.40; 95% CI, 2.0-2.9), age (AOR, 1.03; 95% CI, 1.02-1.04), Hispanic ethnicity (AOR, 1.76; 95% CI, 1.4-2.2), diabetes (AOR, 1.79; 95% CI, 1.6-2.1), and alcohol abuse (AOR, 1.78; 95% CI, 1.5-2.1), whereas black race (AOR, 0.56; 95% CI, 0.48-0.64) and successful eradication of HCV (AOR, 0.61; 95% CI, 0.4-0.9) were protective. Independent risk factors for HCC included HCV infection (AOR, 10.0; 95% CI, 6.1-16.4), HBV infection (AOR, 2.82; 95% CI, 1.7-4.7), age (AOR, 1.05; 95% CI, 1.03-1.08), and low CD4+ cell count (AOR, 2.36; 95% CI, 1.3-4.2). Among 5999 HIV/HCV-coinfected patients, 994 (18%) had ever received HCV antiviral treatment, of whom 165 (17%) achieved sustained virologic response. Conclusion: The prevalence of cirrhosis and HCC has increased dramatically among HIV-infected patients driven primarily by the HCV epidemic. Potentially modifiable risk factors include HCV infection, HBV infection, diabetes, alcohol abuse, and low CD4+ cell count. (Hepatology 2013)
Ovid Technologies (Wolters Kluwer Health)
Title: The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection
Description:
Abstract
Cirrhosis is a leading cause of death among patients infected with human immunodeficiency virus (HIV).
We sought to determine risk factors for and time trends in the prevalence of cirrhosis, decompensated cirrhosis, and hepatocellular carcinoma (HCC) among patients diagnosed with HIV who received care in the Veterans Affairs (VA) health care system nationally between 1996 and 2009 (n = 24,040 in 2009).
Among patients coinfected with HIV and hepatitis C virus (HCV), there was a dramatic increase in the prevalence of cirrhosis (3.
5%-13.
2%), decompensated cirrhosis (1.
9%-5.
8%), and HCC (0.
07%-1.
6%).
Little increase was observed among patients without HCV coinfection in the prevalence of cirrhosis (1.
7%-2.
2%), decompensated cirrhosis (1.
1%-1.
2%), and HCC (0.
03%-0.
13%).
In 2009, HCV infection was present in the majority of patients with HIV who had cirrhosis (66%), decompensated cirrhosis (62%), and HCC (80%).
Independent risk factors for cirrhosis included HCV infection (adjusted odds ratio [AOR], 5.
82; 95% confidence interval [CI], 5.
0-6.
7), hepatitis B virus (HBV) infection (AOR, 2.
40; 95% CI, 2.
0-2.
9), age (AOR, 1.
03; 95% CI, 1.
02-1.
04), Hispanic ethnicity (AOR, 1.
76; 95% CI, 1.
4-2.
2), diabetes (AOR, 1.
79; 95% CI, 1.
6-2.
1), and alcohol abuse (AOR, 1.
78; 95% CI, 1.
5-2.
1), whereas black race (AOR, 0.
56; 95% CI, 0.
48-0.
64) and successful eradication of HCV (AOR, 0.
61; 95% CI, 0.
4-0.
9) were protective.
Independent risk factors for HCC included HCV infection (AOR, 10.
0; 95% CI, 6.
1-16.
4), HBV infection (AOR, 2.
82; 95% CI, 1.
7-4.
7), age (AOR, 1.
05; 95% CI, 1.
03-1.
08), and low CD4+ cell count (AOR, 2.
36; 95% CI, 1.
3-4.
2).
Among 5999 HIV/HCV-coinfected patients, 994 (18%) had ever received HCV antiviral treatment, of whom 165 (17%) achieved sustained virologic response.
Conclusion: The prevalence of cirrhosis and HCC has increased dramatically among HIV-infected patients driven primarily by the HCV epidemic.
Potentially modifiable risk factors include HCV infection, HBV infection, diabetes, alcohol abuse, and low CD4+ cell count.
(Hepatology 2013).
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Interactions Between Human Immunodeficiency Virus–1, Hepatitis Delta Virus and Hepatitis B Virus Infections in 260 Chronic Carriers of Hepatitis B Virus
Interactions Between Human Immunodeficiency Virus–1, Hepatitis Delta Virus and Hepatitis B Virus Infections in 260 Chronic Carriers of Hepatitis B Virus
To evaluate the factors determining the severity of chronic hepatitis B virus infection and the interactions of human immunodeficiency virus and hepatitis delta virus infections, w...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
PERBANDINGAN INDEKS ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX (APRI) PADA PASIEN SIROSIS HEPATIS DAN KARSINOMA HEPATOSELULER
PERBANDINGAN INDEKS ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX (APRI) PADA PASIEN SIROSIS HEPATIS DAN KARSINOMA HEPATOSELULER
ABSTRAK
Sirosis hepatis dianggap sebagai kondisi sebelum terjadinya karsinoma hepatoseluler. Sirosis hepatis dan karsinoma hepatoseluler perlu dideteksi lebih awal dengan men...
Evaluating the GALAD Score in Diagnosing Hepatocellular Carcinoma
Evaluating the GALAD Score in Diagnosing Hepatocellular Carcinoma
This paper aims to evaluate the GALAD score in diagnosing hepatocellular carcinoma. The paper conducted a retrospective study of 86 Hepatocellular Carcinoma patients who underwent ...
PREVALENCE OF HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS IN INJECTION DRUG USERS OF KHYBER PAKHTUNKHWA, AND FACTORS AFFECTING ITS OCCURRENCE
PREVALENCE OF HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS IN INJECTION DRUG USERS OF KHYBER PAKHTUNKHWA, AND FACTORS AFFECTING ITS OCCURRENCE
Objective: Our main objective was to find out the prevalence of Hepatitis C virus and Human immunodeficiency virus and its co presence in injection drug users. We have to show the ...
Long interval between HCV infection and development of hepatocellular carcinoma
Long interval between HCV infection and development of hepatocellular carcinoma
Abstract: A high prevalence of HCV infection has been reported in patients with hepatocellular carcinoma. The progression from acute transfusion‐associated hepatitis to hepatic ci...

